Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.35 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | LAP3 | P28838 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30606392 | 1.00 | TSHR (0.40) | TSHRLMNASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL13155620 | 1.00 | TSHR (0.40) | TSHRLMNASLC1A3SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL10347009 | 0.98 | TSHR (0.39) | TSHRLMNASLC1A3SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL17005230 | 0.98 | TSHR (0.39) | TSHRLMNASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL10205198 | 0.82 | SLC1A2 (0.39) | TSHRLMNASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL15075211 | 0.82 | SLC1A2 (0.39) | TSHRLMNASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL4534790 | 0.81 | TSHR (0.40) | TSHRLMNASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL2494007 | 0.81 | TSHR (0.40) | TSHRLMNASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL27621457 | 0.81 | TSHR (0.40) | TSHRLMNASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL26276763 | 0.81 | SLC1A3 (0.35) | SLC1A3SLC1A2SLC1A1SLC7A5ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109251163-A | A kind of method for splitting of indoline -2- formic acid compound and wherein mesosome | 江苏永达药业有限公司 | 2019-01-22 | — | — | CN | claimed |
| US-20250215465-A1 | ENANTIOSELECTIVE METHODS FOR PREPARING CHIRAL AMINE INTERMEDIATES | UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG (ZA) | 2025-07-03 | — | — | US | disclosed |
| EP-4493708-A1 | ENANTIOSELECTIVE METHODS FOR PREPARING CHIRAL AMINE INTERMEDIATES | University of the Witwatersrand, Johannesburg (ZA) | 2025-01-22 | — | — | EP | disclosed |
| CN-118974266-A | Enantioselective process for preparing chiral amine intermediates | 约翰内斯堡威特沃特斯兰德大学 | 2024-11-15 | — | — | CN | disclosed |
| CN-117534629-A | Triazinone compound and preparation method and application thereof | 贵州大学 | 2024-02-09 | — | — | CN | disclosed |
| WO-2023197017-A1 | ENANTIOSELECTIVE METHODS FOR PREPARING CHIRAL AMINE INTERMEDIATES | UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG (ZA) | 2023-10-12 | — | — | WO | disclosed |
| EP-3102215-B1 | 4'-DIFLUOROMETHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF INFLUENZA RNA REPLICATION | RIBOSCIENCE LLC (US) | 2021-06-16 | — | — | EP | disclosed |
| WO-2019030387-A1 | SOLID COMPOSITION COMPRISING AMORPHOUS SOFOSBUVIR AND AMORPHOUS DACLATASVIR | SANDOZ AG (CH) | 2019-02-14 | — | — | WO | disclosed |
| CN-109251163-A | A kind of method for splitting of indoline -2- formic acid compound and wherein mesosome | 江苏永达药业有限公司 | 2019-01-22 | — | — | CN | disclosed |
| EP-2890704-B1 | 2'-ETHYNYL NUCLEOSIDE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | NOVARTIS AG (CH) | 2018-02-28 | — | — | EP | disclosed |
| US-20090197835-A1 | VINYL PHOSPHONATE LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2009-08-06 | — | — | US | disclosed |
| US-20080318901-A1 | Novel Lysophosphatidic Acid Receptor Selective Antagonists | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080318901-A1 | Novel Lysophosphatidic Acid Receptor Selective Antagonists | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-12-25 | — | — | US | disclosed |
| WO-2008014286-A1 | VINYL PHOSPHONATE LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-01-31 | — | — | WO | disclosed |
| EP-1677791-A4 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-08-15 | — | — | EP | disclosed |
| US-20070088002-A1 | Orally available sphingosine 1-phosphate receptor agonists and antagonists | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-04-19 | — | — | US | disclosed |
| US-20070088002-A1 | Orally available sphingosine 1-phosphate receptor agonists and antagonists | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-04-19 | — | — | US | disclosed |
| EP-1677791-A2 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005044793-A2 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | WO | disclosed |
| US-3979457-A | ACYLASE | DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JA) | 1976-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088002-A1 | Orally available sphingosine 1-phosphate receptor agonists and antagonists | S1PR3, S1PR1, S1PR5 | TSHR 232/4885LMNA 2126/4885SLC1A3 1190/4885 |
| US-20090197835-A1 | VINYL PHOSPHONATE LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR4, LPAR5 | TSHR 509/4885LMNA 2213/4885SLC1A3 2841/4885 |
| US-20250215465-A1 | ENANTIOSELECTIVE METHODS FOR PREPARING CHIRAL AMINE INTERMEDIATES | BCAT1, BCAT2, CES1 | TSHR 1369/4885LMNA 1726/4885SLC1A3 163/4885 |
| US-20080318901-A1 | Novel Lysophosphatidic Acid Receptor Selective Antagonists | LPAR3, LPAR2, LPAR1 | TSHR 475/4885LMNA 2765/4885SLC1A3 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.